Search

Your search keyword '"Ghosh, Soma"' showing total 484 results

Search Constraints

Start Over You searched for: Author "Ghosh, Soma" Remove constraint Author: "Ghosh, Soma"
484 results on '"Ghosh, Soma"'

Search Results

102. Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson’s Disease

107. A Garland of Melodies: Reimagining Ragamalas through the Collection of Salar Jung Museum, Hyderabad.

115. TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis

117. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

118. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

119. PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR

123. Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

127. Nucleoporin-93 Overcomes Multiple Nucleocytoplasmic Trafficking Bottlenecks and Permits Robust Metastasis

132. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions

133. Nucleoporin-93 overexpression overcomes multiple nucleocytoplsamic trafficking bottlenecks to permit robust metastasis

134. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer

135. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer

136. FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

137. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

138. Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson’s Disease.

139. The Art of Shringara: Revisiting the Kishangarh School of Rajasthani Painting.

140. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

142. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

148. PD-L1 Recruits Phospholipase C and Enhances EGFR Signaling: Relevance to Resistance of EGFR-Mutated Lung Tumors to Immunotherapy

Catalog

Books, media, physical & digital resources